[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-351784-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-351784-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","positive-prognostic-implications-of-sphk1-expression-in-patients-with-papillary-thyroid-carcinoma-undergoing-radioactive-iodine-therapy","Positive prognostic implications of SPHK1 expression in patients with papillary thyroid carcinoma undergoing radioactive iodine therapy","","Sphingosine kinase 1 (SPHK1) is a sphingolipid-metabolism enzyme linked to tumor progression, but its role in papillary thyroid carcinoma (PTC) remained unclear. Immunohistochemistry on tissue microarrays from 471 PTC patients quantified SPHK1 by H-score (positivity: H-score ≥10). SPHK1 positivity (18.0%) associated with BRAFp.V600E, and in patients under 55 years it predicted improved recurrence-free survival, especially with radioactive iodine therapy. Multivariate Cox regression confirmed independent favorable prognostic value.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/positive-prognostic-implications-of-sphk1-expression-in-patients-with-papillary-thyroid-carcinoma-undergoing-radioactive-iodine-therapy/351784/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/positive-prognostic-implications-of-sphk1-expression-in-patients-with-papillary-thyroid-carcinoma-undergoing-radioactive-iodine-therapy/351784.png","ImageObject",300,407,{"name":42,"@type":43},"Mabel","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How was SPHK1 expression measured in PTC patients?","Question",{"text":63,"@type":64},"SPHK1 expression was assessed by immunohistochemistry on tissue microarrays from 471 PTC patients, and quantified using the H-score method.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What clinicopathologic factors were associated with SPHK1 positivity?",{"text":68,"@type":64},"SPHK1 positivity (H-score ≥10) was significantly associated with the BRAFp.V600E mutation, but not with tumor size, extrathyroidal extension, or lymph node metastasis.",{"name":70,"@type":61,"acceptedAnswer":71},"Does SPHK1 positivity predict recurrence-free survival, and how does radioactive iodine affect this?",{"text":72,"@type":64},"In patients younger than 55 years, SPHK1 positivity correlated with improved recurrence-free survival, and the prognostic benefit remained significant in the subgroup receiving radioactive iodine therapy.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},351784,1790153990,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},7971474920318,"https://ap-avatar.wpscdn.com/avatar/74000ee537e6b0ca360?x-image-process=image/resize,m_fixed,w_180,h_180&k=1788430171632181674","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nPositive prognostic implications of SPHK1 expression in patients with papillary thyroid carcinoma undergoing radioactive iodine therapy  \nKyung Won Park1, Ja Seong Bae2, Dong-Jun Lim3 & Chan Kwon Jung4,5􀀍  \nSphingosine kinase 1 (SPHK1) is an important enzyme involved in sphingolipid metabolism  \nand has been linked to tumor progression in various cancers. However, its clinical significance in papillary thyroid carcinoma (PTC) remains uncertain. We examined SPHK1 expression using immunohistochemistry on tissue microarrays from 471 patients diagnosed with PTC, with expression levels quantified using the H-score method. SPHK1 positivity, defined as an H-score ≥10, was observed in 85 cases (18.0%) and was significantly associated with the BRAFp.V600E mutation (p \u003C 0.001) but not with tumor size, extrathyroidal extension, or lymph node metastasis. In patients younger than 55 years, SPHK1 positivity was associated with improved recurrence-free survival (RFS) (p = 0.046), and this prognostic benefit remained significant in the subgroup receiving radioactive iodine therapy (p = 0.028) . Multivariate Cox regression analysis confirmed SPHK1 positivity as an independent predictor of favorable RFS (p = 0.036) . Unlike its recognized oncogenic role in other malignancies, SPHK1 may function as a context-dependent biomarker in PTC, particularly among younger patients treated with radioactive iodine, possibly reflecting enhanced immune surveillance or altered tumor– microenvironment interactions. Further investigations are warranted to clarify the immunomodulatory and therapeutic implications of SPHK1 in differentiated thyroid cancer.  \nKeywords Papillary thyroid carcinoma, SPHK1, Sphingosine-1-phosphate, Prognostic biomarker, Recurrence-free survival, Radioactive iodine therapy  \nPapillary thyroid carcinoma (PTC) is the most common subtype of thyroid cancer and is generally associated with excellent long-term survival, especially in younger patients1,2. Historically, total thyroidectomy followed by radioactive iodine (RAI) ablation was the standard treatment, particularly before the 2015 American Thyroid Association (ATA) guidelines were published3. However, as risk-managed strategies have evolved, the current treatment approach increasingly favors thyroid lobectomy for low-to intermediate-risk PTCs2,4. The use of RAI has significantly decreased in recent years. Since PTC patients often have long survival times, with recurrence or late progression potentially happening beyond ten years, cohorts treated with total thyroidectomy and RAI provide a valuable framework for studying long-term prognostic biomarkers. These well-characterized RAItreated cohorts provide a valuable setting for exploring the molecular factors associated with recurrence and disease-free survival.  \nIn our previous study using spatial transcriptomics and immunohistochemical profiling, we identified sphingosine kinase 1 (SPHK1) as a consistently upregulated gene in anaplastic thyroid carcinoma (ATC)5. SPHK1 catalyzes the phosphorylation of sphingosine to generate sphingosine-1-phosphate (S1P), a potent bioactive lipid mediator implicated in diverse cellular processes, including proliferation, survival, angiogenesis, and immune cell trafficking6,7. Aberrant SPHK1/S1P signaling has been implicated in tumor progression, metastasis,  \n1Department of Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.  \n2Department of Surgery, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. 3Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. 4Department of Hospital Pathology, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea. 5Cancer Research Institute, College of Medicine, The Catholic University of Korea, ","cbCaip2r7w7T3F2Q","https://ap.wps.com/l/cbCaip2r7w7T3F2Q","pdf",2552301,11,"English","# Abstract\n# Background\n# Methods\n## Patient cohort and tissue samples\n# Results\n# Conclusions","[{\"question\":\"How was SPHK1 expression measured in PTC patients?\",\"answer\":\"SPHK1 expression was assessed by immunohistochemistry on tissue microarrays from 471 PTC patients, and quantified using the H-score method.\"},{\"question\":\"What clinicopathologic factors were associated with SPHK1 positivity?\",\"answer\":\"SPHK1 positivity (H-score ≥10) was significantly associated with the BRAFp.V600E mutation, but not with tumor size, extrathyroidal extension, or lymph node metastasis.\"},{\"question\":\"Does SPHK1 positivity predict recurrence-free survival, and how does radioactive iodine affect this?\",\"answer\":\"In patients younger than 55 years, SPHK1 positivity correlated with improved recurrence-free survival, and the prognostic benefit remained significant in the subgroup receiving radioactive iodine therapy.\"}]","Positive prognostic implications of SPHK1 expression in patients with papillary thyroid carcinoma undergoing radioactive iodine therapy | PDF",1790095886,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/923527897ccd61f79fa6e0e3b2bc9458.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/08468d16f2039eb1087cb4b7688713c9.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1569b10853f14fc071b71e732b3d8af2.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/45a7e8cb1e9181f6ddee6d407349b63c.webp",980,1287]